COMMITTED TO CHANGING THE FACE OF CANCER TREATMENT
The BioCanRx Board of Directors is responsible for ensuring financial accountability, scientific excellence, knowledge exchange and operational efficiency. The board approves policies and procedures consistent with the goals and mission of the network. It also determines the mandate, membership, authority and makeup of committees.
The Board provides leadership and direction to BioCanRx so that it remains on target with respect to its strategic plan and commitment to the NCE mandate.
MEMBERS OF THE BOARD:
 |
 |
 |
 |
| Ken Newport Chair, Board of Directors |
Dr. Lorne Babiuk Vice-President, Research, University of Alberta |
Dr.John Bell Scientific Director, BioCanRx Senior Scientist, The Ottawa Hospital Professor, uOttawa |
Dr. Elizabeth Douville Founder and Managing Partner, AmorChem Venture Fund |
 |
 |
 |
 |
| Darrell Fox Board Member and Senior Advisor, Terry Fox Research Institute |
Bruce Galloway Former Chair, Ovarian Cancer Canada |
Kendra MacDonald Partner, Deloitte |
Dr. Duncan Stewart CEO and Scientific Director, Ottawa Hospital Research Institute |
 |
 |
 |
|
| Dr. Augusto Villanueva Business Unit Head, Oncology, Merck Canada |
Dr. Christine Williams Deputy Director, Ontario Institute for Cancer Research (OICR) |
Dr. David Young Life Science Entrepreneur and Founder/CEO of Actium Research Inc. |
EX-OFFICIO MEMBERS (NON-VOTING)
 |
| Dr. Stéphanie Michaud President and CEO, BioCanRx Secretary, Board of Directors |
OBSERVERS
 |
| Kimberly Douglas Senior Program Manager, Networks of Centres of Excellence |
